Draupnir Bio

Draupnir Bio is a Danish biotechnology company developing small molecule therapeutics to transform the treatment of heart disease, based on proprietary structural insights and the biology of Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9), a protein that enables a key step in the control of plasma low density lipoprotein cholesterol (LDLC) levels.

The company was founded in 2017 as a spin-out from Aarhus University, Denmark, and the Max-Planck Society, Germany. The company is headquartered in Copenhagen, with research operations centered in Aarhus, Denmark.

Contact name:

Christine Ritter

Address:

c/o COBIS, Ole Maaløes Vej 3, 2200 CPH N

Established:

2017

Number of employees:

12

If you cannot find what you are looking for or if you have feedback to our website, please do not hesitate to contact dd@danskbiotek.dk or +45 5150 0560

Copyright 2020 Danskbiotek. All rights reserved.